R/S-(S)-3-((S)-2-Acetylamino-3-methyl-butyrylamino)-N-{(S)-1-[7-hydroxy-1-((S)-2-hydroxy-5-oxo-tetrahydro-furan-3-ylcarbamoyl)-3,4-dihydro-1H-isoquinoline-2-carbonyl]-2-methyl-propyl}-succinamic acid

ID: ALA1835402

PubChem CID: 56683723

Max Phase: Preclinical

Molecular Formula: C30H41N5O11

Molecular Weight: 647.68

Molecule Type: Small molecule

This compound is available for customization.

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N1CCc2ccc(O)cc2C1C(=O)N[C@H]1CC(=O)OC1O)C(C)C)C(C)C

Standard InChI:  InChI=1S/C30H41N5O11/c1-13(2)23(31-15(5)36)27(42)32-19(11-21(38)39)26(41)34-24(14(3)4)29(44)35-9-8-16-6-7-17(37)10-18(16)25(35)28(43)33-20-12-22(40)46-30(20)45/h6-7,10,13-14,19-20,23-25,30,37,45H,8-9,11-12H2,1-5H3,(H,31,36)(H,32,42)(H,33,43)(H,34,41)(H,38,39)/t19-,20-,23-,24-,25?,30?/m0/s1

Standard InChI Key:  QUNGAOXLQCNBLP-ZOGZNBLASA-N

Molfile:  

     RDKit          2D

 46 48  0  0  0  0  0  0  0  0999 V2000
   15.4083  -11.4141    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0757  -10.9265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.8201  -10.1370    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.9933  -10.1382    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7409  -10.9282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.5033   -9.4671    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   16.8556  -11.1777    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   15.4050  -12.2411    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.7019  -12.6752    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.0293  -13.9405    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.8818  -14.0309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5905  -13.6105    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    6.1652  -13.6265    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.8917  -14.8558    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    8.3113  -14.0149    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0222  -13.5944    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3212  -14.8398    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6103  -15.2603    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0420  -15.2443    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7408  -13.9989    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.0123  -12.7695    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   10.4475  -13.5784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1683  -13.9829    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.4376  -12.7535    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.1782  -14.8078    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.1527  -12.3330    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8747  -12.7391    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.1440  -11.5098    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   11.8770  -13.5625    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.5978  -13.9669    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3064  -13.5465    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6077  -14.7918    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.8968  -15.2123    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3221  -15.1963    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.3066  -12.7215    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.0543  -14.7647    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.7305  -13.4996    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.9786  -12.2861    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.7837  -15.1494    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4603  -13.8924    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.4820  -14.7142    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.2062  -15.1053    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.9054  -14.6764    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8817  -13.8500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.1567  -13.4645    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.5827  -13.4150    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  1  0
  4  5  1  0
  1  5  1  0
  4  6  2  0
  2  7  1  0
  1  8  1  1
 11 12  1  0
 11 13  1  0
 11 14  2  0
 12 15  1  0
 15 16  1  0
 15 17  1  6
 17 18  1  0
 17 19  1  0
 16 20  1  0
 16 21  2  0
 20 22  1  0
 22 23  1  0
 22 24  1  1
 23 25  2  0
 24 26  1  0
 26 27  1  0
 26 28  2  0
 23 29  1  0
 29 30  1  0
 30 31  1  0
 30 32  1  6
 32 33  1  0
 32 34  1  0
 31 10  1  0
 31 35  2  0
 10 36  1  0
 10 37  1  0
 36 39  1  0
 40 37  1  0
 37  9  1  0
  9  8  1  0
  9 38  2  0
 41 39  1  0
 40 41  2  0
 41 42  1  0
 42 43  2  0
 43 44  1  0
 44 45  2  0
 45 40  1  0
 44 46  1  0
M  END

Associated Targets(Human)

CASP2 Tchem Caspase-2 (173 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CASP3 Tchem Caspase-3 (3632 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Biocomponents

Calculated Properties

Molecular Weight: 647.68Molecular Weight (Monoisotopic): 647.2803AlogP: -1.17#Rotatable Bonds: 12
Polar Surface Area: 240.77Molecular Species: ACIDHBA: 10HBD: 7
#RO5 Violations: 2HBA (Lipinski): 16HBD (Lipinski): 7#RO5 Violations (Lipinski): 3
CX Acidic pKa: 4.25CX Basic pKa: CX LogP: -1.11CX LogD: -4.11
Aromatic Rings: 1Heavy Atoms: 46QED Weighted: 0.13Np Likeness Score: 0.41

References

1. Maillard MC, Brookfield FA, Courtney SM, Eustache FM, Gemkow MJ, Handel RK, Johnson LC, Johnson PD, Kerry MA, Krieger F, Meniconi M, Muñoz-Sanjuán I, Palfrey JJ, Park H, Schaertl S, Taylor MG, Weddell D, Dominguez C..  (2011)  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.,  19  (19): [PMID:21903398] [10.1016/j.bmc.2011.08.020]
2. Chen, Yi-Hua YH and 9 more authors.  2006-03-09  Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.  [PMID:16509578]
3. Maillard, Michel C MC and 17 more authors.  2011-10-01  Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.  [PMID:21903398]

Source